81 results about "Synzyme" patented technology

This invention relates to a method for producing chondroitin with improved safety and extracellular secretion levels, belonging to the field of genetic engineering. Using the probiotic *Escherichia coli* Nissle 1917 as the host, this invention designs methods to increase chondroitin production by studying the chondroitin synthase KfoAC and the chondroitin-linking Kdo synthase. The relationship between chondroitin synthesis and secretion in *E. coli* was clarified, and the specificity of the chondroitin-linking Kdo was investigated, resulting in an extracellular chondroitin production of 0.32 g / L. Subsequently, the introduction of the protein KfoB from the chondroitin synthesis gene cluster increased the extracellular chondroitin production to 0.51 g / L. Further screening and optimization of the expression of transport proteins resulted in an extracellular chondroitin production of 0.73 g / L in shake flasks. Further optimization using a 7-L fermenter resulted in an extracellular chondroitin production of 5.9 g / L.

The present application relates to the technical field of fermentation engineering, and provides an engineered Escherichia coli for producing uroporphyrin as well as a construction method and application thereof.The present application uses Escherichia coli to express porphyrin synthase of thermophilic bacteria, performs whole-cell catalysis of 5-ALA to synthesize uroporphyrin under high-temperature conditions, and completely shields endogenous regulation; further, the Escherichia coli is wrapped by COF material to prevent the loss of enzymes in the cell recovery process; and a protein scaffold based on dockerin-cohesin is constructed to further improve the yield of uroporphyrin III.The present application creates a brand-new uroporphyrin high-temperature whole-cell catalysis process, realizes the efficient production of uroporphyrin, and provides a basis and idea for the industrial production of uroporphyrin.

This invention relates to the fields of bioengineering and fermentation engineering, and discloses a genetically engineered *Streptomyces albopictus* strain that produces high levels of ε-polylysine and its fermentation production process. This genetically engineered strain uses *Streptomyces albopictus* strains acclimated to ε-polylysine tolerance as a chassis, and its genome integrates... ppc and dapf Through expression box, heterogeneous asd Expression cassettes, containing secretory signal peptides lysp Fusion expression cassettes and D404A / K499A point mutations pls Expression cassette. The fermentation process employs a two-stage pH control strategy, maintaining a neutral environment during the cell growth phase and adjusting to an acidic environment during product synthesis. This invention improves ε-polylysine yield through a synergistic strategy of enhancing precursor supply, constructing efflux detoxification channels, and increasing synthase activity; combined with an acidic fermentation process, it effectively inhibits product degradation, yielding a high-molecular-weight and highly uniform target product suitable for industrial production.

This application discloses a cyclic GMP-AMP synthase mutant. Compared to the wild-type cyclic GMP-AMP synthase shown in SEQ ID NO.1, the amino acid sequence of the cyclic GMP-AMP synthase mutant has any one of the following mutations: L377M or H437T / S434T. Specifically, the amino acid sequence of the L377M mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.4, and the amino acid sequence of the H437T / S434T mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.9. The cGAS mutant of this application exhibits four times the activity of the wild-type. The preparation method uses readily available and economical raw materials, is simple to operate, environmentally friendly, and pollution-free, with high synthesis efficiency, making it suitable for industrial development.

The present disclosure relates to animal models that express human tryptophanyl-tRNA synthetase (hWARS) knock-in. These animal models are highly susceptible to enterovirus infection, including but not limited to EV-D68 and EV-A71 infection. Also disclosed are screening methods and compounds that utilize these animal models.

The present disclosure relates to a method for improving the quality of glycosylated antibody drug conjugates (DAR distribution, stability, etc.) using activated carbon. Specifically, the present disclosure employs hydrophobic interaction chromatography (HIC) column, protein A chromatography, activated carbon stirring, and buffer exchange, alone or in series, to remove free glycosyltransferases. As a result, the purity of the glycosylated antibody drug conjugates is improved, and the degradation of the antibody drug conjugates is prevented. Ultimately, the drug substance (DS) of OBI-902 (anti-TROP2 antibody drug conjugate) and OBI-904 (anti-Nectin-4 antibody drug conjugate) is further determined.

The present disclosure relates to methods, compositions and kits for treating conditions that are related to the modulation of expression of 5′-Aminolevulinate Synthase 1 (ALAS1) by gene editing.

The application provides a myo-inositol-3-phosphate synthase mutant, which is obtained by mutating a myo-inositol-3-phosphate synthase with an amino acid sequence as shown in SEQ ID NO: 4 at positions 55, 57 and 273 respectively. The application also provides a preparation method of myo-inositol. The inventors have screened a wild-type myo-inositol-3-phosphate synthase and a myo-inositol monophosphatase with good performance, which can be used in cooperation with a glucan phosphorylase and a glucose phosphate mutase to catalyze starch to generate myo-inositol more efficiently. The myo-inositol-3-phosphate synthase mutant is applied to in-vitro non-fermentation biosynthesis of myo-inositol, combined with myo-inositol monophosphatases E1 and E5, and in a way of feeding whole cells, so that starch can be converted into myo-inositol in a one-pot method, without using NAD + coenzymes, and has a good industrial application prospect.

This invention belongs to the field of biotechnology and discloses a recombinant strain of Saccharomyces cerevisiae that enhances the efficient synthesis of vitamin K2 and its application. By heterologously integrating the hepS / T and naphthoquinone cyclotransferase genes (menA) of Bacillus subtilis, four genetically engineered strains were constructed based on the designed MK-7 biosynthetic pathway: YK-1, YK-2, YK-3, and YK-4. YK-1 is an expression strain containing the target genes MenF, MenD, and MenH; YK-2 is an expression strain integrating the target genes MenC, MenE, and MenB on the basis of YK-1; YK-3 is an expression strain integrating the target genes hepS and hepT on the basis of YK-2; and YK-4 is an expression strain integrating the target genes yuxO, MenA, and MenG on the basis of YK-3. YK-4 is the final engineered strain that produces high levels of vitamin K2. The optimal fermentation time was determined by measuring OD600 and yield curves. YK-4 reached its maximum cell concentration in 18 hours, which can effectively shorten the fermentation cycle.

The purpose of the present invention is to provide: a plant having an increased yield of storage tissue; and a method for producing the plant. It was discovered that the yield of storage tissue in a plant can be increased by expressing, in the storage tissue of the plant, a sucrose synthase having a substrate specificity to adenosine diphosphate.

The application belongs to the technical field of biological medicine, and particularly relates to an anti-aging ergothioneine composition for improving mitochondrial function and a preparation method thereof. The composition comprises the following components: ergothioneine, sea hao polysaccharide and entada extract. The ergothioneine has good mitochondrial targeted antioxidant activity, can up-regulate the expression of Sirt1 to activate PGC-1a, and promote mitochondrial biosynthesis; the sea hao polysaccharide is helpful to restore mitochondrial function, promote the generation of mitochondrial high-energy phosphoric compounds, improve cell activity and energy supply for regeneration, and can up-regulate the expression of key genes for mitochondrial biosynthesis and ATP synthase related genes. The entada extract can synergize with the ergothioneine and the sea hao polysaccharide, significantly down-regulate the expression of aging related proteins such as p53, p21 and p16 in cells, simultaneously inhibit the transcription of aging related genes, and has a good protective effect on aging cells.

This invention belongs to the field of agricultural herbicides and provides a photosynthetic inhibitor herbicidal composition comprising 5-aminolevulinic acid, malondialdehyde, and a herbicidal active ingredient. The herbicidal active ingredient is selected from one or a combination of several herbicides selected from acetolactate synthase inhibitors, photosynthetic system II inhibitors, or protoporphyrinogen oxidase (PPO) inhibitors. This invention utilizes the synergistic effect of 5-aminolevulinic acid, malondialdehyde, and a specific type of herbicidal active ingredient to effectively enhance the efficacy of the herbicidal active ingredient, enabling rapid and thorough weed control.

The present invention relates to an antibody specifically binding to a tryptophanyl-tRNA synthetase (WRS) protein and, more specifically, to: an antibody, or a fragment of the antibody, specifically binding to a polypeptide of an amino acid sequence represented by SEQ ID NO: 2 in a WRS protein; a polynucleotide encoding the antibody and a vector comprising same; a cell transformed using same; and a use thereof.

This invention discloses a mango terpene synthase gene TPS4 and its applications, the nucleotide sequence of which is shown in SEQ ID NO:1. The amino acid sequence of the protein it encodes is shown in SEQ ID NO:2. The invention also discloses a recombinant expression vector containing the mango terpene synthase gene TPS4, a recombinant engineered strain, and the recombinant mango terpene synthase TPS4; and the application of the mango terpene synthase gene TPS4, its encoded protein, the recombinant expression vector, the recombinant engineered strain, or the recombinant TPS4 in regulating the synthesis of terpenoid compounds from geraniol diphosphate (GPP), neroli diphosphate (NPP), and farnesyl diphosphate (FPP). This invention is the first to clone and verify a terpene synthase gene TPS4 from the Sacred Heart mango genome, capable of simultaneously catalyzing the synthesis of monoterpenes and sesquiterpenes from three substrates: GPP, NPP, and FPP. It has broad application prospects and significant economic value.

This invention belongs to the field of biological breeding technology, specifically involving SlCSLA2 Application of genes in improving the storage and transportability of tomato fruit. This invention addresses the industry problem of severe storage and transport losses in tomatoes due to excessive softening after harvest. For the first time, it utilizes CRISPR / Cas9 gene editing technology to knock out the cell wall hemicellulose (mannan) synthase gene. SlCSLA2 This invention has led to the creation of a tomato mutant with significantly enhanced fruit firmness. The firmness of the entire fruit during the red-ripe stage is 35%–42% higher than that of the wild type, and the firmness can be maintained for about a week after harvest, effectively delaying the softening process and significantly improving storage and transportability. This invention provides new gene targets and technical approaches for breeding tomato varieties with improved storage and transportability.

This invention generally relates to the field of therapeutic compounds. More specifically, this invention relates to 2-amino- N -(oxo-aryl-λ) 6 (-Thionyl)acetamide compounds (referred to herein as ANOSA compounds), said compounds In particular Inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetases (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also relates to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in vitro and in vivo to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetases; to treat conditions improved by inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetases; to treat bacterial infections; and so on.

The application discloses application of ZmGOLS2 genes and ZmRAFS genes in improving pollen vitality of corn under heat shock and drought conditions, and belongs to the technical field of genetic engineering. The application improves the pollen vitality of corn, promotes the germination of pollen under heat shock and drought stress conditions, and reduces the empty stalk rate of corn under drought stress conditions by simultaneously improving the expression levels of a corn myo-inositol galactoside synthetase coding gene and a corn raffinose synthetase coding gene.

The present invention relates to a method for obtaining a functionally enhanced mitochondria and a use thereof, and specifically, to: a mitochondria isolated from cells overexpressing glutathione synthase; and a use thereof for preventing, alleviating, or treating muscle weakness-related diseases.

This invention discloses an enzymatic method for preparing (S)-adenosylmethionine. The method uses adenosine diphosphate (ADP) and L-methionine as substrates, reacting them under the combined action of polyphosphate kinase (Ppk) and adenosylmethionine synthase (MAT) to obtain (S)-adenosylmethionine. This method produces a product with high chiral purity and high atom economy, making it more suitable for industrial production.

The present disclosure relates to an L-arginine-producing microorganism in which the activity of a regulator of nitrate reductase operon expression is attenuated and the activity of glutamine synthetase is enhanced, and to a method for producing L-arginine using same, wherein the L-arginine-producing microorganism, in which the activity of the regulator of nitrate reductase operon expression is attenuated and the activity of glutamine synthetase is enhanced, has been confirmed to exhibit increased L-arginine production capability compared to a parent strain, and thus can be widely used for L-arginine production.

The application discloses a kind of amide bond synthesis enzyme mutant and its application in catalyzing synthesis of drug intermediate, the mutant is P328A-T421L, and its amino acid sequence is as shown in SEQ ID NO:5.A kind of amide bond synthesis enzyme mutant in catalyzing synthesis of drug intermediate, with 2-methylthiazole-5-carboxylic acid and L-O-methyl serine as substrate, with mutant P328A-T421L or the mutant P328A shown in SEQ ID NO:3 as catalyst, drug intermediate is obtained in one step reaction, and the drug intermediate is O-methyl-N-(2-methylthiazole-5-formyl)-L-serine (MTCS).The performance of the mutant of the application compared with wild type, the performance of catalyzing synthesis of peptide epoxy ketone proteasome inhibitor oplazomib core chiral precursor MTCS is greatly improved, and conversion rate is increased from 26.8% of wild type to 76.1%.

The present application relates to the technical field of genetic engineering, and discloses a recombinant Escherichia coli for high-yield O-acetyl-L-homoserine and application thereof. The recombinant Escherichia coli for high-yield O-acetyl-L-homoserine is obtained by the following combination of modification strategies: in Escherichia coli W3110, a gene encoding homoserine O-acetyltransferase is integrated into a gene site encoding L-arginine ABC transporter ATP binding subunit, then a gene encoding phosphoacetyltransferase is knocked out, then a gene encoding transcriptional anti-terminator and mRNA stability regulator is knocked out, then a gene encoding ATP-NAD kinase is integrated into a gene site encoding NADPH-dependent aldehyde reductase, and finally a gene promoter of acetyl-CoA synthetase is replaced by a Ptrc promoter to obtain the recombinant Escherichia coli. The recombinant Escherichia coli is used for fermentation to produce O-acetyl-L-homoserine, and has the advantage of high yield. metx artp patz cspc ppnk yahk acs ​​​​​​​

This invention discloses an antimicrobial peptide, its pharmaceutical composition, and its applications. The invention optimizes the structure of the antimicrobial peptide through deuteration modification technology, significantly enhancing its targeted binding ability to β-1,3-D-glucan synthase. The affinity of this antimicrobial peptide for the aforementioned target is 9-27 times that of the control peptide. In vitro assays show that its minimum inhibitory concentration (MIC) against nine standard Candida strains is consistently 0.002 μg / mL, exhibiting significantly superior activity compared to fluconazole, anidoxurine, and the control peptide. It also exhibits extremely low cytotoxicity against L02 human normal hepatocytes. In in vivo experiments, in a neutropenic mouse model of Candida albicans infection, the antimicrobial peptide at all doses showed superior reduction in renal fungal load compared to anidoxurine and the control peptide. The antimicrobial peptide of this invention combines highly efficient anti-Candida activity, low cytotoxicity, and excellent in vivo efficacy, providing a safe and effective candidate drug for the treatment of drug-resistant candidiasis and possessing good clinical translational value.

This invention provides a hydrogen production reaction system using formaldehyde and water as co-substrates, comprising a buffer solution, maltodextrin, formaldehyde, magnesium chloride, manganese chloride, NAD, benzyl viologen, sodium phosphate, α-glucan phosphorylase, phosphogluconomutase, glucose-6-phosphate dehydrogenase, phosphogluconate dehydrogenase, phosphogluconolactonease, flavoxase, hydrogenase, 6-phosphate hexulose synthase, phosphogluconose isomerase, and phosphogluconose isomerase. This invention also provides a corresponding hydrogen production method. This invention utilizes formaldehyde and water to generate hydrogen, avoiding excessive dependence on agricultural resources; simultaneously, by replacing traditional carbohydrates with high-energy formaldehyde as the substrate, it lowers the energy barrier of the co-substrate water and simplifies the process of carbohydrate miniaturization and hydrogen production; furthermore, it has the advantages of being less demanding in terms of water quality conditions and having low cost.

The invention provides an S-adenosine homocysteine (SAH) analogue, an S-adenosine-L-methionine (SAM) analogue and application thereof. The preparation method comprises the following steps: synthesis of the SAH analogue and a fluoroalkyl SAM analogue, fluoromethylation modification of bioactive molecules by an HMT-MT cyclase cascade reaction system based on the fluoroalkyl SAM analogue, and construction of a fluoro derivative of a clinical drug synthesized by a one-pot enzymatic method. The SAH analogue adopted by the invention can effectively avoid spontaneous degradation of the corresponding SAM analogue, and is used for constructing a cascade reaction system based on HMT-MT cyclase, so that the yield of a fluoromethylation product is increased; it is confirmed that the fluoro-intermediate generated by MT can be accepted by downstream biosynthetase, so that a fluoro-derivative of a clinical drug synthesized by a one-pot enzymic method is constructed.

The present disclosure provides alkoxy thiophene acyl arylamine compounds and a use thereof, comprising alkoxy thiophene acyl arylamine compounds having a structure as shown in formula (1), or pharmaceutically acceptable salts thereof. The alkoxy thiophene acyl arylamine compounds provided by the present disclosure are a class of novel sphingomyelin synthase inhibitors, which have significant inhibitory activity against SMS2, ideal physical and chemical properties such as stability and water solubility, and low potential for toxic side effects, and can be further made into a drug for preventing or treating diseases related to abnormal sphingomyelin levels

Recombinant cells and methods for producing methyl ketones, such as medium-chain methyl ketones. The recombinant cells include recombinant acyl-ACP thioesterase genes, recombinant β-ketoacyl-CoA thioesterase genes, and recombinant acyl-CoA synthetase genes, in addition to other modifications. The methods include culturing the recombinant cells to produce the methyl ketones and isolating the produced methyl ketones.

Provided are gamma glutamylcysteine synthetase variants and microbial cells comprising such variants and / or expressing heterologous gamma-glutamylcysteine synthetase-glutathione synthetases, for producing increased amounts of the antioxidant peptide glutathione (GSH). Methods and compositions provided herein may be useful in baking and winemaking applications and in production of nutraceuticals, pharmaceuticals, cosmetics, plant protectants and / or animal feeds.

Nucleic acid molecules comprising truncated forms of the human cytomegalovirus (CMV) promoter are operably linked to a transgene of interest, including those encoding eNOS protein are taught. Vectors comprising these nucleic acid molecules and host cells transformed by these vectors and methods of producing cellular compositions are used for the treatment of a variety of pulmonary and cardiac diseases. There is provided a truncated human cytomegalovirus (CMV) enhancer element comprising SEQ ID NO: 1 or a functional derivative thereof. A truncated human cytomegalovirus (CMV) promoter comprising the truncated CMV enhancer element is taught. A polynucleotide expression cassette comprising the truncated CMV promoter and a transcribable polynucleotide operably linked to the truncated CMV promoter polynucleotide construct, a host cell comprising the polynucleotide expression cassette, and use of the host cell treat renal, vascular, pulmonary, or cardiac disease in the patient are taught.

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds. Also described herein are methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.